HRP20140262T1 - Biomarker za praä†enje pacijenata - Google Patents
Biomarker za praä†enje pacijenata Download PDFInfo
- Publication number
- HRP20140262T1 HRP20140262T1 HRP20140262AT HRP20140262T HRP20140262T1 HR P20140262 T1 HRP20140262 T1 HR P20140262T1 HR P20140262A T HRP20140262A T HR P20140262AT HR P20140262 T HRP20140262 T HR P20140262T HR P20140262 T1 HRP20140262 T1 HR P20140262T1
- Authority
- HR
- Croatia
- Prior art keywords
- patient
- specified
- activated
- levels
- treatment
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title claims 2
- 238000012544 monitoring process Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (9)
1. Postupak ex-vivo procjenjivanja djelotvornosti liječenja koje uključuje primjenu imunogenog pripravka koji sadrži najmanje jedan rekombinantni virusni vektor koji kodira ciljani antigen za pacijenta, naznačen time što se sastoji u:
– mjerenju razina aktiviranih CD3+ CD69+ T-limfocita u biološkom uzorku uzetom iz organizma navedenog pacijenta, gdje su jedna ili više doza navedenog imunogenog pripravka primijenjene na navedenom pacijentu i gdje je navedeni biološki uzorak uzet nakon najmanje jedne od navedenih primjena;
– gdje razine aktiviranih CD3+ CD69+ T-limfocita iznad otprilike 10,4% ukazuju da subjekt pokazuje uspješan klinički ishod liječenja.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što je uspješan klinički ishod povećanje stope preživljenja.
3. Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni imunogeni pripravak dodatno sadrži najmanje jedan modifikator imunosnog odgovora.
4. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni pacijent boluje od raka.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što je navedeni rak rak velikih stanica pluća ili rak bubrega.
6. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što navedeni ciljani antigen je tumorski specifični antigen.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time što je navedeni tumorski specifični antigen MUC1.
8. Upotreba razina aktiviranih CD3+ CD69+ T-limfocita kao biomarkera za praćenje, modificiranje ili podešavanje liječenja koje uključuje primjenu imunogenog pripravka koji sadrži najmanje jedan rekombinantni virusni vektor koji kodira ciljani antigen za pacijenta, naznačena time što razine aktiviranih CD3+ CD69+ T-limfocita iznad otprilike 10,4% ukazuju da subjekt pokazuje uspješan klinički ishod liječenja.
9. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što je navedeni uspješan klinički ishod povećanje stope preživljenja.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09305328 | 2009-04-17 | ||
PCT/EP2010/054743 WO2010119003A1 (en) | 2009-04-17 | 2010-04-12 | Biomarker for monitoring patients |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140262T1 true HRP20140262T1 (hr) | 2014-04-25 |
Family
ID=42270292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140262AT HRP20140262T1 (hr) | 2009-04-17 | 2014-03-20 | Biomarker za praä†enje pacijenata |
Country Status (27)
Country | Link |
---|---|
US (2) | US20120058493A1 (hr) |
EP (1) | EP2419728B1 (hr) |
JP (1) | JP5661738B2 (hr) |
KR (1) | KR20120027146A (hr) |
CN (1) | CN102395883B (hr) |
AU (1) | AU2010237215B2 (hr) |
BR (1) | BRPI1010512A2 (hr) |
CA (1) | CA2759050A1 (hr) |
CO (1) | CO6440591A2 (hr) |
CR (1) | CR20110513A (hr) |
CY (1) | CY1114910T1 (hr) |
DK (1) | DK2419728T3 (hr) |
ES (1) | ES2445146T3 (hr) |
HK (1) | HK1163246A1 (hr) |
HR (1) | HRP20140262T1 (hr) |
IL (1) | IL214917A (hr) |
MX (1) | MX2011010920A (hr) |
NZ (1) | NZ594896A (hr) |
PL (1) | PL2419728T3 (hr) |
PT (1) | PT2419728E (hr) |
RU (1) | RU2555340C2 (hr) |
SG (1) | SG175060A1 (hr) |
SI (1) | SI2419728T1 (hr) |
SM (1) | SMT201400046B (hr) |
TW (1) | TWI426270B (hr) |
WO (1) | WO2010119003A1 (hr) |
ZA (1) | ZA201107545B (hr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6375947B2 (ja) * | 2012-05-11 | 2018-08-22 | 味の素株式会社 | 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置 |
US20140244556A1 (en) * | 2013-02-27 | 2014-08-28 | Abdul Saleh | Methods for and apparatus generating automated pharmaco genetics correlation |
WO2019113449A1 (en) * | 2017-12-08 | 2019-06-13 | Stc.Unm | In vivo imaging of tumor infiltration leukocytes |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
US6054438A (en) | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
ES2267100T5 (es) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | Oligonucleótidos inmunomoduladores. |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
DE19520606B4 (de) | 1995-06-06 | 2004-04-08 | Roche Diagnostics Gmbh | Vorrichtung zur optischen Untersuchung von Oberflächen |
DE69638058D1 (de) | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
EP1012276A2 (en) | 1997-02-24 | 2000-06-28 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
FR2773885B1 (fr) | 1998-01-16 | 2000-03-03 | Elf Antar France | Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode |
JP3119228B2 (ja) | 1998-01-20 | 2000-12-18 | 日本電気株式会社 | 液晶表示パネル及びその製造方法 |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
EP1147181B1 (en) | 1999-02-04 | 2004-05-12 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
DE60029195T2 (de) | 1999-02-22 | 2007-06-28 | Transgene S.A. | Verfahren zur Gewinnung von purifizierter Virenzusammensetzung |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
DK1230378T3 (da) | 1999-11-15 | 2007-10-08 | Onyx Pharma Inc | Et onkolytisk adenovirus |
AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
NZ524661A (en) | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
WO2004011082A1 (en) | 2002-07-26 | 2004-02-05 | Myomend, Inc. | Cardiac rhythm management system with intramural myocardial pacing leads and electrodes |
BR0315810A (pt) | 2002-10-29 | 2005-09-13 | Coley Pharmaceutical Group Ltd | Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c |
FR2862648B1 (fr) | 2003-11-21 | 2006-02-03 | Biomerieux Sa | Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c |
ES2526344T3 (es) * | 2005-06-28 | 2015-01-09 | Oncothyreon Inc. | Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1) |
US20100150969A1 (en) * | 2006-12-05 | 2010-06-17 | Bruce Acres | immune response |
JP5642666B2 (ja) * | 2008-05-29 | 2014-12-17 | トランジェーヌ、ソシエテ、アノニムTransgene S.A. | 患者選択のためのバイオマーカーおよび関連方法 |
-
2010
- 2010-04-12 BR BRPI1010512A patent/BRPI1010512A2/pt not_active IP Right Cessation
- 2010-04-12 NZ NZ594896A patent/NZ594896A/xx not_active IP Right Cessation
- 2010-04-12 PT PT107192858T patent/PT2419728E/pt unknown
- 2010-04-12 ES ES10719285.8T patent/ES2445146T3/es active Active
- 2010-04-12 DK DK10719285.8T patent/DK2419728T3/da active
- 2010-04-12 SG SG2011072360A patent/SG175060A1/en unknown
- 2010-04-12 PL PL10719285T patent/PL2419728T3/pl unknown
- 2010-04-12 CN CN201080016800.2A patent/CN102395883B/zh not_active Expired - Fee Related
- 2010-04-12 AU AU2010237215A patent/AU2010237215B2/en not_active Ceased
- 2010-04-12 EP EP10719285.8A patent/EP2419728B1/en not_active Not-in-force
- 2010-04-12 SI SI201030533T patent/SI2419728T1/sl unknown
- 2010-04-12 RU RU2011146419/15A patent/RU2555340C2/ru not_active IP Right Cessation
- 2010-04-12 WO PCT/EP2010/054743 patent/WO2010119003A1/en active Application Filing
- 2010-04-12 CA CA2759050A patent/CA2759050A1/en not_active Abandoned
- 2010-04-12 JP JP2012505138A patent/JP5661738B2/ja not_active Expired - Fee Related
- 2010-04-12 US US13/264,946 patent/US20120058493A1/en not_active Abandoned
- 2010-04-12 KR KR1020117024190A patent/KR20120027146A/ko active IP Right Grant
- 2010-04-12 MX MX2011010920A patent/MX2011010920A/es active IP Right Grant
- 2010-04-16 TW TW099112032A patent/TWI426270B/zh not_active IP Right Cessation
-
2011
- 2011-09-01 IL IL214917A patent/IL214917A/en not_active IP Right Cessation
- 2011-09-29 CR CR20110513A patent/CR20110513A/es unknown
- 2011-10-14 CO CO11136970A patent/CO6440591A2/es not_active Application Discontinuation
- 2011-10-14 ZA ZA2011/07545A patent/ZA201107545B/en unknown
-
2012
- 2012-03-14 HK HK12102541.6A patent/HK1163246A1/xx not_active IP Right Cessation
-
2014
- 2014-01-08 US US14/150,503 patent/US20140141039A1/en not_active Abandoned
- 2014-02-13 CY CY20141100110T patent/CY1114910T1/el unknown
- 2014-03-20 HR HRP20140262AT patent/HRP20140262T1/hr unknown
- 2014-04-03 SM SM201400046T patent/SMT201400046B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
MX2019002904A (es) | Composiciones de arn de alta pureza y métodos para su preparación. | |
PH12017501583A1 (en) | Novel proteins specific for cd137 | |
MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
WO2015138357A3 (en) | Compositions useful in treatment of otc deficency | |
NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
UA126380C2 (uk) | Генно-інженерний вірус вісповакцини | |
EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
MX2022004042A (es) | Proteinas de union multiespecificas para tratamiento contra el cancer. | |
HRP20140915T1 (hr) | Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo | |
IN2014DN05670A (hr) | ||
WO2012069568A3 (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
NZ708144A (en) | Recombinant adenoviruses and use thereof | |
MX345700B (es) | Proteinas f del vrs modificadas y metodos de uso de las mismas. | |
WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
NZ612405A (en) | Nucleic acid molecules that target the vacuolar atpase c subunit and confer resistance to coleopteran pests | |
MX2009008118A (es) | Polipeptido e2 del virus del papiloma usado para vacunacion. | |
EA201391737A1 (ru) | Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы | |
BR112013030150A2 (pt) | proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
WO2012083302A3 (en) | Compositions and methods for the treatment or prevention of human adenovirus-36 infection | |
PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
HRP20140262T1 (hr) | Biomarker za praä†enje pacijenata | |
HRP20171697T1 (hr) | Varijanta hiv gp-120 |